- Why Work With NSF?
NSF Pharma Biotech has helped companies that have been placed on import alert and have had their products subject to detention without physical examination (DWPE). We can determine what conditions are causing the import alert and assist your company with the remediation of these conditions. In addition, we can interface with the agency with your approval to help better understand the actions required to lift the import alert.
For more information about NSF Pharma Biotech regulatory enforcement action support in the U.S., email email@example.com or call +1 202.822.1850.
For more information about NSF Pharma Biotech regulatory enforcement action support in Europe, email firstname.lastname@example.org or call +44 1751 432 999.
Why Work With NSF?
Our team includes former U.S. FDA inspectors and experts who have a proven track record for addressing the most complex regulatory problems and compliance issues. We can interface with the agency on your behalf to help you to better understand the actions needed to lift the import ban.
- 1 week ago
FDA Regulatory and Compliance News FDA announced the approval of Bayer HealthCare Pharmaceuticals’ Avelox (moxifloxacin) to treat patients with pneumonic...
- 2 weeks ago
FDA Regulatory and Compliance News FDA republished in its entirety a final order entitled, “Medical Devices; Physical Medicine Devices; Classification...
- 2 months ago
ANN ARBOR, Mich. – Global public health organization NSF International has published the first American National Standard for pharmaceutical excipients...
- Monday, June 1, 2015
- 8:30am - 4:00pm GMT
- Manchester, United Kingdom
- Tuesday, June 2, 2015
- 9:00am - 3:00pm GMT
- Manchester, UK, United Kingdom
- Thursday, June 4, 2015
- 8:30am - 3:00pm GMT
- York, United Kingdom
- Thursday, June 11, 2015
- 1:00pm - 2:00pm GMT
- Webinar, United Kingdom